PB2115: TRIAL IN PROGRESS: A RANDOMIZED PHASE II STUDY OF MB-CART2019.1 COMPARED TO STANDARD OF CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION

• P. Borchmann,
• P. Vandenberghe,
• A. Urbano,
• C. Haioun,
• F. Lemonnier,
• L. Griškevicius,
• S. Maury,
• S. Holtkamp,
• B. Friedrichs,
• G. Zadoyan,
• L. Hanssens,
• C. Brillant,
• U. Bethke,
• M. Assenmacher,
• I. Bürger,
• B. Philippe,
• T. Overstijns,
• U. Jäger,
• M. J. Kersten

Affiliations

P. Borchmann

1 Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany

P. Vandenberghe

2 Department of Hematology, University Hospital Leuven, Leuven, Belgium

A. Urbano

3 Institut Clinic de Malaties Hematologiques i Oncologiques (ICMHO), Hospital Clinic de Barcelona, Barcelona, Spain

C. Haioun

4 AP-HP, Henri Mondor University Hopital, Créteil, France

F. Lemonnier

4 AP-HP, Henri Mondor University Hopital, Créteil, France

L. Griškevicius

5 Santaros Klinikos, Vilnius University Hospital, Vilnius, Lithuania

S. Maury

4 AP-HP, Henri Mondor University Hopital, Créteil, France

S. Holtkamp

6 Miltenyi Biomedicine GmbH

B. Friedrichs

6 Miltenyi Biomedicine GmbH

G. Zadoyan

6 Miltenyi Biomedicine GmbH

L. Hanssens

6 Miltenyi Biomedicine GmbH

C. Brillant

7 Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany

U. Bethke

7 Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany

M. Assenmacher

7 Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany

I. Bürger

7 Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany

B. Philippe

7 Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany

T. Overstijns

6 Miltenyi Biomedicine GmbH

U. Jäger

8 Department of Hematology and Hemostaseology, University Hospital Vienna, Vienna, Austria

M. J. Kersten

9 Department of Hematology, Amsterdam University Medical Centers, Amsterdam, Netherlands